Genetic linkage studies have led to the identification of highly penetrant genes as the possible cause of inherited cancer risk in many cancer-prone families. Most women with a family history of breast/ ovarian cancer have tumors characterized by alterations in particular genes, mainly BRCA1 and BRCA2, but also CHK2, ATM, STK11 and others. This paper examines the BRCA1 and BRCA2 genes, focusing on the Italian pattern of mutations. The function of these two genes, classified as tumor suppressors, is linked with key metabolic mechanisms such as DNA damage repair, regulation of gene expression and cell cycle control. The pathological BRCA allelic variants may cause alteration of protein function, transcriptional activity and DNA repair; accumulation of the defects leads to widespread chromosome instability that may be directly responsible for cancer formation. In fact, mutations in BRCA1 and BRCA2, conferring a highly increased susceptibility to breast and ovarian cancer, do not lead to cancer by themselves. The current consensus is that these are 'caretaker' genes, which, when inactivated, allow other genetic defects to accumulate. The nature of these other molecular events may define the pathway through which BRCA1 and BRCA2 act. The BRCA mutation spectrum is complex, and the significance of most nucleotide alterations is difficult to understand. Moreover, the mutation pattern seems to be related to ethnicity. The Italian Consortium of Hereditary Breast and Ovarian Cancer has reviewed 1758 families; 23% have been found to be carriers of pathogenetic mutations in BRCA1 or BRCA2. Founder mutations have been described in geographically restricted areas of Italy; a regional founder effect has been demonstrated in Italy for the mutations BRCA1 5083del19 and BRCA2 8765delAG, and a probable new founder mutation has been characterized in Tuscany. The presence of founder mutations has practical implications for genetic testing.
Introduction
That there may be a genetic contribution to breast cancer risk is indicated by the increased incidence of breast cancer among women with a family history of the disease and by the observation of families in which multiple members have breast cancer in a pattern compatible with autosomal dominant inheritance of cancer susceptibility.
Linkage analysis studies of families have led to the identification of highly penetrant genes as the possible cause of inherited cancer risk in many cancer-prone families [1] . However, mutations in these genes are rare, and account for no more than 5-10% of breast cancer cases. It is probably that other background genetic factors contribute to the etiology of breast malignancies [2] .
Autosomal dominant inherited predisposition to breast cancer is characterized by early age at onset, bilaterality, vertical transmission through both maternal and paternal lines, and familial association with tumors of other organs.
Three principal syndromes are associated with autosomal dominant inheritance of breast cancer risk: (i) hereditary breast and ovarian cancer due to BRCA1 or BRCA2 germline mutations [3] ; (ii) Li-Fraumeni syndrome due to germline mutations in the p53 gene, identified in over 50% of families, with a penetrance of at least 50% by age 50 years [3, 4] ; germline mutations in another gene, hCHK2, have been implicated in the etiology of classical and variant Li-Fraumeni families [5] ; and (iii) Cowden syndrome due to PTEN germline mutations [3] . Mutations in each of these genes produce different clinical phenotypes of characteristic malignancies.
Other genetic syndromes, which may include breast cancer, are ataxia telangiectasia and Peutz -Jeghers syndrome. Ataxia telangiectasia is an autosomal recessive disorder; it is estimated that 1% of the general population may be heterozygote carriers of the ATM gene [6] . Over 200 mutations have been identified in the gene to date, the majority of which are truncating mutations [7] . A number of epidemiological studies have suggested a statistically increased risk of breast cancer among female heterozygote carriers, with an estimated relative risk ranging from 3.9 to 6.4 [8] . Peutz-Jeghers syndrome is an early onset autosomal dominant disorder [9] . Germline mutations in STK11 appear to be responsible for 50% of Peutz -Jeghers syndrome cases [10] . Patients with this syndrome have a very high risk of developing breast cancer [11] .
Identification of the BRCA1 and BRCA2 genes marked an important step in understanding the molecular basis of the hereditary susceptibility to cancer [12, 13] .
BRCA1 and BRCA2 genes BRCA1 is mapped to chromosome 17q21 [1] ; it contains 24 exons and encodes a protein of 220 kDa, composed of 1863 amino acids [14] .
The second breast cancer susceptibility gene, BRCA2, is localized on the long arm of chromosome 13. BRCA2 is also a large gene, with 27 exons that encode a protein of 380 kDa, composed of 3418 amino acids [15] .
Although they are not homologous genes, both BRCA1 and BRCA2 have an unusually large exon 11 and translational start site in exon 2. Their proteins are normally located in the nucleus and contain phosphorylated residues [14, 15] . BRCA1 contains only two recognizable protein motifs, a RING finger domain near the N-terminus and a BRCT domain at the C-terminus. RING fingers are cysteine-rich sequences that coordinate the binding of two zinc ions and are found in a number of diverse proteins. This type of domain may facilitate both protein-protein and protein-DNA interactions. The BRCT domain is a phylogenetically conserved sequence found in proteins involved in DNA repair and cell cycle regulation [16] . BRCA2 has no recognizable protein motifs and has no apparent relation to BRCA1.
Nonetheless, BRCA1 and BRCA2 appear to share a number of functional similarities that may suggest why mutations in these genes lead to a specific hereditary predisposition to breast and ovarian cancer. The precise biological function of these genes and how their mutations can induce cancer susceptibility at present remain unclear, although it is known that BRCA proteins are involved in several cellular processes, such as control of genome integrity, and cell growth and differentiation [17, 18] .
Scientific evidence suggests that BRCA1 and BRCA2 are directly involved in the DNA repair process [17, 19] , regulation of gene expression and embryogenesis [20] . In fact, the products of both genes interact with different proteins involved in homologous chromosome recombination and double-strand break repair mechanisms [19] . These findings are important not only for elucidating the mechanisms of BRCA tumor induction, but also may suggest a novel genotype-based approach to choosing therapies for breast cancer in women with BRCA mutations [21] .
BRCA1 and BRCA2 allelic variants BRCA1 and BRCA2 seem to behave as tumor suppressor genes, with tumor specimens revealing loss of the unmutated allele ( Figure 1 ) [22, 23] . Women carrying germline mutations in one BRCA1 or BRCA2 allele thus have an extremely high lifetime risk of developing breast and/or ovarian cancer [24] .
The pathological BRCA allelic variants may cause altered function of the proteins, altered transcriptional activity and/or altered DNA repair; the accumulation of defects results in diffuse chromosome instability, which could be directly responsible for cancer formation. In fact, mutations in BRCA1 and BRCA2, conferring a highly increased susceptibility to breast and ovarian cancer, do not lead to cancer by themselves. The current consensus is that these are 'caretaker' genes, which, when removed, allow other genetic defects to accumulate. The nature of these other molecular events may define the pathway through which BRCA1 and BRCA2 function.
Nearly 2000 distinct sequence variants in BRCA1 and BRCA2 have already been described (Breast Cancer Mutation Data, http://www.nhgri.nih.gov/Intramural_research/ Lab_transfer/Bic/), and the pattern of mutations is highly complex and heterogeneous. In both genes, the variants are uniformly distributed along the entire coding regions and intronic sequences flanking each exon. The mutations that have usually been associated with increased risk of cancer (pathogenetic alterations) result in missing complete protein sequences or non-functional proteins (frameshift, nonsense and splice site), thus supporting the hypothesis that BRCA1 and BRCA2 are tumor suppressor genes ( Figure 1) .
The search for mutations is a complex task that depends particularly on the molecular sensitivity of screening methods and on interpretation of the results. Mutation screening methods vary in their sensitivity. Methods widely used in research laboratories, such as single-strand conformational polymorphism (SSCP) analysis and conformation sensitive gel electrophoresis (CSGE), miss nearly one-third of the mutations that are detected by DNA sequencing [25] . In addition, large genomic rearrangements are left undetected by most of the techniques currently used for clinical testing, including direct DNA sequencing. Such rearrangements are believed to be responsible for 10-15% of BRCA1-inactivating mutations [26, 27] . The significance of other nucleotide alterations is very difficult to understand. Missense variants, occurring outside any particular functional domain and thus apparently without pathological significance, may result in altered protein activity or changes in the intronic region that could modify RNA processing.
It is possible that no mutation is identified in high-risk families, owing to complex genetic heterogeneity, while other cancer predisposing genes may confer an increased risk of breast cancer [28] [29] [30] .
The complexity of mutation spectra has also been confirmed in the Italian population. In fact, the Italian Consortium of Hereditary Breast and Ovarian Cancer (nine Units) has examined 1758 families, and 405 (23%) were carriers of pathogenetic mutations (251 in BRCA1 and 154 in BRCA2). To date, a total of 248 mutational pedigrees have been recorded in a centralized data bank in Pisa (147 families with a BRCA1 mutation and 101 families with a BRCA2 mutation).
It is evident that BRCA1 and BRCA2 mutations show different expressivity with respect to breast, ovarian and other cancers, and allelic heterogeneity may be present in both genes (Table 1 ). In particular, in the Pisa Unit, 106 families were screened for BRCA1 and BRCA2 point mutations and small deletions. The families were grouped as hereditary breast cancer (n = 69), hereditary breast and ovarian cancer (n = 33) or hereditary ovarian cancer (n = 4). Mutation analyses were performed by automatic direct sequencing. A total of 46 families (43%) were to be carriers of BRCA1/2 pathogenetic mutations. No pathogenetic mutations were detected in 60 families (57%), and multiple different variants of uncertain biological significance were found.
Similar results were obtained in a preliminary study on a consecutive series of 300 newly diagnosed breast cancer patients, grouped as belonging to high-risk families according to the Myriad Genetic categories and who underwent surgery at the National Cancer Institute of Bari, Italy. Among these patients, 11 had a high risk of carrying a BRCA mutation (Myriad II software) and 75% of them, actually presenting a pathologic mutation evaluated by direct sequencing, also developed ovarian cancer.
Frequency of pathological allelic variants: founder mutations
The vast majority of BRCA mutations have been reported in only a few families (private mutations). A small number of these mutations have been repeatedly found in unrelated families in the same geographical area or within the same ethnic group (founder effects).
Approximately 1 in 800 individuals in the general population may carry a pathogenetic mutation in BRCA1. The frequency for carriers of BRCA1 pathogenetic mutations has been measured in different selected groups of families [31, 32] .
The best characterized examples of founder mutations have been described in Ashkenazi Jews (BRCA1 185delAG and BRCA2 6174delT). Carrier frequencies for these mutations have been determined in the general Jewish population: 1% for 185delAG and 1.5% for 6174delT [33] . Overall, the frequency of these two mutations is 1 in 50 i9 Ashkenazi Jews; it accounts for 25% of early-onset breast cancer and has been found in up to 90% of families with multiple cases of both breast and ovarian cancer among this ethnic group [34] . Additional founder mutations have been described in The Netherlands (BRCA1 2804delAA), Iceland (BRCA2 995del5) and Sweden (BRCA1 3171ins5) [35, 36] . Founder mutations have also been reported in geographically restricted areas of Italy. A regional founder effect has been demonstrated in Italy for BRCA1 5083del19 and BRCA2 8765delAG [37, 38] . A probable new founder mutation has been characterized in Tuscany [39] , where preliminary haplotype analysis of 11 families detected carriers of 1499insA mutation in the BRCA1 gene and identified a specific haplotype associated with the mutation that is found with an appreciable frequency in the general population. The presence of this shared haplotype strongly suggests a founder effect for the BRCA1 1499insA mutation in Tuscany.
The presence of these founder mutations has practical implications for genetic testing. Many laboratories could offer directed testing specifically for 'ethnic-specific' alleles.
Pathological allelic variants and breast cancer risk BRCA1 appears to be responsible for disease in 45% of families with multiple cases of breast cancer only and up to 90% of families with both breast and ovarian cancer, while BRCA2 mutations are thought to account for 35% of multiple-case breast cancer families, and are also associated with male breast cancer, ovarian cancer, prostate cancer and pancreatic cancer [40, 41] .
Estimates of penetrance (percentage of individuals carrying a given mutation who will manifest the disease) for BRCA1 and BRCA2 mutations range from 36% to 85% for breast cancer and from 16% to 60% for ovarian cancer.
Initial penetrance estimates for BRCA1 and BRCA2 mutations were generated from high-risk families (Table 2) . Most families, however, do not fall into the highest of risk categories (e.g. more than four relatives in the same biological line affected), so penetrance values were then calculated on inferred data from a population-based study by comparing the family history of cancer in mutation carriers with that of noncarriers (Table 2 ) [24, 42] . An accurate evaluation of the risk of breast cancer was estimated in carriers of three Ashkenazi BRCA1 and BRCA2 mutations (185delAG and 5382insC in BRCA1, and 6174delT in BRCA2) and in BRCA2 995del5 mutation carriers in an Icelandic population [43, 44] . The penetrance values for breast cancer in carriers of these mutations ranged from 56% to 3%, depending on age. Men carrying BRCA1 and BRCA2 mutations had a slightly increased risk of prostate cancer; neither male nor female carriers were at increased risk of colon cancer, but a greater risk of both these cancers was reported in the Breast Cancer Linkage Consortium families [45] .
However, the other mutations detected up to now may be associated with different degrees of risk, so a precise risk estimate for each mutation cannot be determined.
Pathological allelic variants: models for prediction of the likelihood of being a mutation carrier Emperical models and statistical models have been developed to estimate the personal likelihood of having a BRCA1 or BRCA2 mutation.
All models are based on personal history (breast cancer at an early age, bilateral breast cancer, a history of both breast and ovarian cancer, presence of breast cancer in one or more male family members), family characteristics (multiple cases of breast cancer in the family, both breast and ovarian cancer in the family, one or more family members with two primary cancers) and ethnic background [46, 47] . Emperical studies use populations data derived from clinical referral centers (Table 3) .
Statistical computer programs have been developed to estimate probabilities based on data entered by a health professional [46] [47] [48] . One of these is BRCAPRO, which considers the structure of a family's pedigree, including affected and unaffected family members, and the prevalence, penetrance and mutation frequency to estimate the probability of the presence of a BRCA1 or BRCA2 mutation. BRCAPRO also includes data regarding age at ovarian and breast cancer diagnosis, presence of bilateral breast cancer, male breast cancer and Ashkenazi Jewish heritage.
At present, additional studies are underway to further validate these models.
Allelic variants and pathology of breast cancer
The phenotype for BRCA-related tumors appears to be heterogeneous (Table 4) , and to date is better characterized in BRCA1 than in BRCA2 [49] . The histopathological features of breast cancer in women with BRCA1 mutations showed a greater number of high-grade tumors, a relative lack of in situ components adjacent to invasive lesions, high mitotic rates, high total grade, high rates of aneuploidy and high proliferative fractions, lack estrogen receptor-negative and increased frequency of high-intensity immunostaining for p53; higher rate of medullary cancer histotype have also been reported [50] . 
